(571) 447-5500

EAS Blog

EAS Independent Consultants and staff provide in-depth regulatory expertise and authoritative reporting on a variety of compliance requirements for industries that EAS serves. Our experts break down complicated topics into easily understandable summaries and analysis. Subscribe to our newsletter and receive these monthly updates directly in your in-box.

How to Build an Achieving Team

How to Build an Achieving Team

By Eiman Raouf, EAS Senior Regulatory ConsultantUpon entering various organizations, scenarios often unfold where operational efficiency falls short. Quality lapses in production, a surge in customer grievances, or perpetual crisis management seem to be the norm rather than the exception....

read more
Drug and Device July 2024

Drug and Device July 2024

FDA has sent notices to drug establishment registrants reminding OTC hand sanitizer manufacturers who entered the market solely to provide hand sanitizer during the COVID-19 public health emergency, that beginning FY2025 OMUFA facility user fees will become mandatory. The FDA had previously...

read more
FDA Enhances Tobacco Retailer Inspection Database

FDA Enhances Tobacco Retailer Inspection Database

This week, FDA’s Center for Tobacco Products updated the presentation of information about tobacco compliance check outcomes on the FDA website and expanded the information available. The newly-named Tobacco Compliance Check Outcomes database provides an enhanced user experience by housing results...

read more
Import Refusals – “Don’t Panic”

Import Refusals – “Don’t Panic”

By Mark Moen, EAS Consulting Group Senior Regulatory ConsultantProducts imported into the US may be assessed and inspected by US Customs and Border Protection (CBP), the Food and Drug Administration (FDA), and US Consumer Products Safety Commission (CPSC). US Customs and Border Protection (CBP) is...

read more
Drug and Device June 2024

Drug and Device June 2024

Final reminder that CARES Act drug amount reports for 2023 are due by 31 July 2024. If you need assistance with this process, reach out to Victoria Pankovich for support.The FDA announced the availability of a final guidance for industry titled “Facility Readiness: Goal Date Decisions Under...

read more
FDA Releases Update of Priority Guidance Topics for Foods Program

FDA Releases Update of Priority Guidance Topics for Foods Program

Earlier this year, the FDA released the draft and final guidance topics that are a priority for the agency’s Foods Program to complete during 2024. Since January, the FDA has issued the following guidances that were on the list: New Dietary Ingredient (NDI) Notifications and Related Issues: NDI...

read more
Product Claim Substantiation

Product Claim Substantiation

By Jay Ansell, EAS Independent ConsultantSubstantiating a product claim is required by U.S. law and can help brands avoid regulatory action or provide an effective defense in litigation. For example, in April 2023, the US Federal Trade Commission (FTC), responsible for enforcing federal laws...

read more
Drug and Device May 2024

Drug and Device May 2024

Final reminder that OMUFA facility user fees are due 1 June 2024. Per MoCRA, responsible persons are required to submit any serious adverse event reports to the FDA within 15 business days of receiving such report. Cosmetic labels are required to include a domestic address, domestic phone number,...

read more
Quality Management System (QMS) Documentation

Quality Management System (QMS) Documentation

By Jeff VanderHoek, EAS Independent ConsultantThe design and manufacturing of medical devices requires a high level of quality and reliability to ensure patient safety and regulatory compliance. The Quality Management System (QMS) that a company creates and puts in place plays a key role in...

read more
Drug and Device April 2024

Drug and Device April 2024

FDA announced the fiscal year 2024 OTC-Monograph Drug User Fee rates in the Federal Register Vol 89, No. 62 published 29 March 2024. These fees cover FDA’s FY2024 which runs from October 2023 through September 2024.  The facility fees for FY 2024 are due on 3 June 2024. Regarding fee specifics,...

read more
US label and EU label: food labeling in comparison

US label and EU label: food labeling in comparison

Gisela Leon, EAS Consulting Group Independent ConsultantInterviewed for Industrie- und Handelskammer HannoverApril 4, 2024Published in GermanWithin the European Union, food labeling is clearly regulated. In the USA, too, it is - but different. The Food and Drug Administration (FDA) and the United...

read more
Control of Cronobacter in Dairy Dryer and Packaging Rooms

Control of Cronobacter in Dairy Dryer and Packaging Rooms

By Beth Koenig, EAS Independent ConsultantWhat Is Cronobacter and Why Should We Be Concerned About It? Cronobacter, a genus of bacterial pathogens in the Enterobacteriacea family is of considerable concern in infant formula manufacturing and in the manufacture of products for populations with...

read more
FY2024 OMUFA User Fees Announced by FDA

FY2024 OMUFA User Fees Announced by FDA

FDA announced the fiscal year 2024 OTC-Monograph Drug User Fee rates in the Federal Register Vol 89, No. 62 published 29 March 2024. These fees cover FDA’s FY2024 which runs from October 2023 through September 2024. The facility fees for FY 2024 are due on 3 June 2024. Regarding fee specifics,...

read more
FDA Launches Searchable Tobacco Products Database

FDA Launches Searchable Tobacco Products Database

Database Lists Tobacco Products—Including E-Cigarettes—That May Be Legally MarketedToday, FDA launched the Searchable Tobacco Products Database, a new user-friendly list of tobacco products—including e-cigarettes—that may be legally marketed in the United States. The database is designed to serve...

read more
Drug and Device March 2024

Drug and Device March 2024

Reminder that CARES volume 2023 reports are due no later than 1 July 2024.Highlighted Guidance Documents Reporting Amount of Listed Drugs and Biological Products Technical Conformance Guide FDA is issuing this Technical Conformance Guide to assist registrants of drug establishments in submitting...

read more
Reassessment of EMPs

Reassessment of EMPs

Reassessment of EMPs: Have You Identified the Correct Sampling Locations to Protect Your Product?An EAS Complimentary Webinar Presented by Rocelle Grabarek, EAS Independent ConsultantMarch 27, 2024 • 1pm (Eastern) 1.5 hoursMany of the environmental monitoring programs (EMP) have been established...

read more
Are You Ready for the Unspoken Challenges of FSMA 204?

Are You Ready for the Unspoken Challenges of FSMA 204?

By Norman Alayan, EAS Independent Consultant“The FDA final rule on Requirements for Additional Traceability Records for Certain Foods (Food Traceability Final Rule) establishes traceability record-keeping requirements, beyond those in existing regulations, for persons who manufacture, process,...

read more
Drug and Device February 2024

Drug and Device February 2024

The FDA has issued a final Guidance Document to assist drug establishment registrants with understanding the CARES Act reporting requirements. Reporting Amount of Listed Drugs and Biological Products Under Section 510(j)(3) of the FD&C Act guidance offers very detailed instructions for...

read more
Media Spotlight: EAS Consultant John Bailey

Media Spotlight: EAS Consultant John Bailey

John Bailey, an EAS consultant and the former director of FDA’s Office and Cosmetics and Colors, shared his thoughts with KFF Health News on FDA’s Plan to Ban Hair Relaxer Chemical Called Too Little, Too Late. Read...

read more
Conducting Remote Regulatory Assessments Questions and Answers

Conducting Remote Regulatory Assessments Questions and Answers

FDA is issuing the draft guidance to describe the Agency’s current thinking regarding its use of remote regulatory assessments in order to increase industry’s understanding of RRAs and facilitate FDA’s process for conducting RRAs. FDA has used RRAs to conduct oversight, mitigate risk, meet...

read more